John,That's the big “IF” isn’t? IF the company gets FDA approval...

John,

That's the big “IF” isn’t? IF the company gets FDA approval for bile duct and IF the company sells its Oncosil devices and IF the company actually gets reimbursed from health/hospital authorities in Europe and Asia and IF the TGA approves the Oncosil device for sale in Australia and IF the Hong Kong authorities approve the sale of the device in Hong Kong and IF the company secured some sort of strategic partner for China and Japan and perhaps the US. And the BIG one IF the company actually designs a suitable pivot trial for LAPC that is approved by the FDA and IF the pivot trial is successful and the FDA finally approves the Oncosil device for LAPC.

Yes, if all those BIG IF’s are achieved then you would expect a significant rerate of the company by the market.

But so far we have not seen many of those “IF’s” come to fruition. Have we?